微血管密度作为膀胱癌的一个预后因素：文献系统综述与荟萃分析

Microvessel density as a prognostic factor in bladder cancer: a systematic review of literature and meta-analysis.

作者信息

Huang Juan, Ma Xuelei, Chen Xiangjun, Liu Xiaoxiao, Zhang Binglan, Minmin Li, Nie Wen, Zhang Lei, Liu Lei

机构信息

Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China.

Department of Obstetrics and Gynecology, Chengdu Integrated TCM & Western Medical Hospital, Chengdu, Sichuan, China.

出版信息

Cancer Biomark. 2014;14(6):505-14. doi: 10.3233/CBM-140417.

DOI:10.3233/CBM-140417

PMID:25335742

Abstract

BACKGROUND

Many studies have shown that microvessel density (MVD) could play a potential value as prognostic biomarkers of tumors. The aim of this systematic review and meta-analysis is to evaluate the association between MVD and survival in patients with bladder cancer.

METHODS

Relevant literature was identified using PubMed and EMBASE. The eligible studies were assessed for quality using REMAPK (REporting recommendations for tumor MARKer prognostic studies (REMARK)). The patients' clinical characteristics and survival outcomes in eligible studies were extracted. And then, data were synthesized to evaluate the prognostic role of the MVD in bladder cancer with hazard ratio (HR), while the heterogeneity among studies was examined using the I^{2}.

RESULTS

This meta-analysis included 10 eligible studies conducted between 1998 and 2011 dealing with bladder cancer. The combined HRs and 95% confidence interval [95% CI] for disease-free survival (DFS) was 2.24 [1.20,4.17], for overall survival (OS) was 1.16 [1.02,1.33] and 1.68 [1.15,2.45] for disease-specific survival (DSS).There was evidence heterogeneity between studies, and the disease stage was a key factor for heterogeneity in subgroup analysis.

CONCLUSIONS

Our studies suggested that high MVD was significantly associated with poor survival and MVD could serve as a prognostic biomarker in patients with bladder cancer.

摘要

背景

许多研究表明，微血管密度（MVD）可能作为肿瘤预后生物标志物具有潜在价值。本系统评价和荟萃分析的目的是评估MVD与膀胱癌患者生存之间的关联。

方法

通过PubMed和EMBASE检索相关文献。使用REMAPK（肿瘤标志物预后研究报告建议（REMARK））对纳入研究进行质量评估。提取纳入研究中患者的临床特征和生存结局。然后，采用风险比（HR）综合数据评估MVD在膀胱癌中的预后作用，同时使用I²检验研究间的异质性。

结果

该荟萃分析纳入了1998年至2011年间进行的10项关于膀胱癌的纳入研究。无病生存（DFS）的合并HR及95%置信区间[95%CI]为2.24[1.20,4.17]，总生存（OS）为1.16[1.02,1.33]，疾病特异性生存（DSS）为1.68[1.15,2.45]。研究间存在证据异质性，疾病分期是亚组分析中异质性的关键因素。